17-Jan-2025
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
Seeking Alpha News (Fri, 17-Jan 6:57 AM ET)
QIAGEN Finalizes $300 Million Synthetic Share Repurchase Plan
TipRanks (Thu, 16-Jan 5:27 PM ET)
Business Wire (Thu, 16-Jan 4:05 PM ET)
Qiagen (QGEN) Gets a Hold from Kepler Capital
TipRanks (Thu, 16-Jan 6:38 AM ET)
Qiagen N.V. Voting Rights Update: BlackRock’s Significant Stake Disclosed
TipRanks (Wed, 15-Jan 4:36 PM ET)
Qiagen Announces BlackRock’s Significant Voting Rights in Recent AFM Disclosure
TipRanks (Wed, 15-Jan 4:36 PM ET)
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
Business Wire (Wed, 15-Jan 8:13 AM ET)
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
Business Wire (Sun, 12-Jan 1:05 PM ET)
Business Wire (Fri, 10-Jan 1:30 AM ET)
Business Wire (Thu, 9-Jan 4:05 PM ET)
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Qiagen N.V. Common Shares trades on the NYSE stock market under the symbol QGEN.
As of January 17, 2025, QGEN stock price climbed to $46.00 with 998,496 million shares trading.
QGEN has a market cap of $10.20 billion. This is considered a Large Cap stock.
Last quarter Qiagen N.V. Common Shares reported $502 million in Revenue and $.57 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.03.
In the last 3 years, QGEN traded as high as $52.89 and as low as $35.81.
The top ETF exchange traded funds that QGEN belongs to (by Net Assets): IWR, IWD, IWS, BBH, IWB.
QGEN has underperformed the market in the last year with a return of -0.2%, while SPY returned +28.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in QGEN shares. However, QGEN has outperformed the market in the last 3 month and 2 week periods, returning +7.8% and +2.3%, while SPY returned +3.0% and +1.0%, respectively. This indicates QGEN has been having a stronger performance recently.
QGEN support price is $45.27 and resistance is $46.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QGEN shares will trade within this expected range on the day.